Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

>124,311$

110,39812.6

%Tyvaso

109,45881,21034.8

%Adcirca

43,72630,22444.7

%Other

3,1113,745(16.9)

%Total net revenues

$

280,606$

225,57724.4

%Revenues for the quarter ended June 30, 2013 increased by $55.0 million, compared to the same quarter in 2012. The growth in product revenues reflects the continuing increase in the number of patients being treated with our products.

Expenses

The table below summarizes research and development expense by major project and non-project components (dollars in thousands):Three Months EndedJune 30,PercentageChange20132012Project and non-project component:Cardiopulmonary

$

28,537$

22,05829.4

%Share-based compensation expense

14,1584,221235.4

%Other

11,92210,82010.2

%Total research and development expense

$

54,617$

37,09947.2

%Cardiopulmonary. The $6.5 million increase in cardiopulmonary program expense for the quarter ended June 30, 2013, compared to the same quarter in 2012, resulted from increases in expenses incurred related to the development of oral treprostinil and our TransCon once-daily injectable prostacyclin analogues.

Share-based compensation. The increase in share-based compensation of $9.9 million for the quarter ended June 30, 2013, compared to the same quarter in 2012, resulted from the appreciation in the price of our common stock.

The table below summarizes selling, general and administrative expense by major categories (dollars in thousands):Three Months Ended June 30,PercentageChange20132012Category:General and administrative

$

35,445$

31,23313.5

%Sales and marketing

17,34417,1361.2

%Share-based compensation expense

18,5764,889280.0

%Total selling, general and adminis
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
5. Prevagen® is the Number One Branded Memory Supplement in the United States
6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
10. SoundConnect Announces Lync Release in the United States
11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... USA (PRWEB) September 16, 2014 “Nature ... create the features that we desire in optical design,” ... at Montana State University. “As we explore surfaces and ... of those lessons were presented in San Diego in ... Light: Light in Nature ” chaired by Shaw and ...
(Date:9/16/2014)... --The emerging field of molecular electronics could take ... enabling the construction of tiny circuits from molecular ... would take on the roles currently played by ... of researchers from five Japanese and Taiwanese universities ... small-scale electronics: a molecule called picene. In a ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... European Commission,s Joint Research Centre (JRC) has just ... a representative range of 25 different types of ... ensure consumer protection and confidence in many innovative ... most promising technological developments. By enabling a harmonised ...
... Feb. 14, 2011 New England Biolabs has expanded its ... One Taq Hot Start DNA Polymerases. Optimized blends of ... these new products offer robust amplification across a wide range ... exonuclease activity of Deep Vent increases the fidelity and robustness ...
... N.C., Feb. 14, 2011 India,s premier CRO, ... Society of India & Congress of Neurological Surgeons ...  The event was a convergence of leading neuroscientists, ... across the globe to discuss advances made in ...
Cached Biology Technology:Small material, big impact 2New England Biolabs Introduces OneTaq™ DNA Polymerase, a Robust Solution for Routine and Difficult PCR 2Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India 2
(Date:9/16/2014)... Health at the Mailman School of Public Health are ... and prenatal exposure to two phthalates used in a ... the journal Environmental Health Perspectives . , ... levels of the chemicals, butylbenzyl phthalate (BBzP) and di-n-butyl ... increase in risk of developing asthma between age 5 ...
(Date:9/16/2014)... maternal morbidity amongst women in Australia is increased ... published today (17 September) in BJOG: An ... Australians generally enjoy high standards of living; however, ... in particular between indigenous and non indigenous Australians. ... independent impact of socioeconomic position on severe maternal ...
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3
... Cambridge, Mass. - August 10, 2011 - Between conception ... meters long, looping and coiling within the tiny abdomen. ... loops into the same formationhowever, until now, it has ... experimental observations, biological and biophysical manipulations, theory, and computation, ...
... help overcome a major barrier to the use of gene ... reported development and successful initial laboratory tests of such a ... David Kaplan and colleagues note that gene therapy ... requires safe and efficient carriers or "vectors." Those carriers ...
... , Working out the structure of a complex formed ... be key in understanding how an antibiotic-producing organism controls ... example of how other antibiotic producers regulate export to ... certain microorganisms is a complex and highly regulated process, ...
Cached Biology News:Gut coils with help from its elastic neighbor 2Gut coils with help from its elastic neighbor 3Student brings home new expertise to answer question in antibiotic resistance 2Student brings home new expertise to answer question in antibiotic resistance 3
... Psychology, The University of New South Wales, Sydney, ... Perth, Australia This is the Fourth Edition of ... It is a large format version (330 ... compact 3rd edition. This product number includes ...
... Jouan RC10 series of vacuum concentrators/centrifugal evaporators ... features allied to rapid and safe concentration ... be combined with oil-free or high vacuum ... a wide selection of rotors (eliminating sample ...
... is Thermo Electron's most advanced personal gradient ... to use sophisticated onboard software and a ... to offer performance, accuracy and simplicity in ... of customer driven features built up on ...
Carrier Serum...
Biology Products: